Book contents
- Frontmatter
- Contents
- Contributors
- Preface
- Section one Overviews
- Section two Molecules for Chemical Genomics
- Section Three Basics of High-Throughput Screening
- Section Four Chemical Genomics Assays and Screens
- Chapter 12 Basics of HTS Assay Design and Optimization
- Chapter 13 Molecular Sensors for Transcriptional and Post-Transcriptional Assays
- Chapter 14 Time-Resolved Fluorescence Resonance Energy Transfer Technologies in HTS
- Chapter 15 Compound Profiling with High-Content Screening Methodology
- Chapter 16 Use of Transgenic Zebrafish in a Phenotypic Screen for Angiogenesis Inhibitors
- Chapter 17 Flow Cytometry Multiplexed Screening Methodologies
- Chapter 18 Label-Free Biosensor Technologies in Small Molecule Modulator Discovery
- Chapter 19 Basic Principles and Practices of Computer-Aided Drug Design
- Chapter 20 Computational Approach for Drug Target Identification
- Section five Chemical Genomics and Medicine
- Index
- References
Chapter 16 - Use of Transgenic Zebrafish in a Phenotypic Screen for Angiogenesis Inhibitors
from Section Four - Chemical Genomics Assays and Screens
Published online by Cambridge University Press: 05 June 2012
- Frontmatter
- Contents
- Contributors
- Preface
- Section one Overviews
- Section two Molecules for Chemical Genomics
- Section Three Basics of High-Throughput Screening
- Section Four Chemical Genomics Assays and Screens
- Chapter 12 Basics of HTS Assay Design and Optimization
- Chapter 13 Molecular Sensors for Transcriptional and Post-Transcriptional Assays
- Chapter 14 Time-Resolved Fluorescence Resonance Energy Transfer Technologies in HTS
- Chapter 15 Compound Profiling with High-Content Screening Methodology
- Chapter 16 Use of Transgenic Zebrafish in a Phenotypic Screen for Angiogenesis Inhibitors
- Chapter 17 Flow Cytometry Multiplexed Screening Methodologies
- Chapter 18 Label-Free Biosensor Technologies in Small Molecule Modulator Discovery
- Chapter 19 Basic Principles and Practices of Computer-Aided Drug Design
- Chapter 20 Computational Approach for Drug Target Identification
- Section five Chemical Genomics and Medicine
- Index
- References
Summary
Angiogenesis inhibitors have become essential tools in the treatment of diseases such as cancer, age-related macular degeneration, psoriasis, and diabetic retinopathy (reviewed in [1]), making angiogenesis a clinically relevant target process for drug discovery. For example, solid tumors require an adequate supply of blood vessels in order to survive, grow, and metastasize [2, 3]. Recently, a link between angiogenesis and Alzheimer's disease has also been postulated [4], possibly highlighting another clinical use for antiangiogenesis drugs.
Multiple in vitro and in vivo angiogenesis assays are commonly used for drug discovery. Each of these assays has distinct advantages and disadvantages [5 –7]. In vitro endothelial cell models of migration, proliferation, apoptosis, and tube formation are popular because of their simplicity and throughput. However, most of these models address only the effects of compounds on endothelial cells and not other tissues in the vascular bed, such as smooth muscle cells, fibroblasts, and endothelial progenitor cells. Because angiogenesis involves the proliferation and migration of endothelial cells in the context of a living organism, current in vitro models employed in screening campaigns may prove vulnerable to a variety of unanticipated limitations.
- Type
- Chapter
- Information
- Chemical Genomics , pp. 225 - 231Publisher: Cambridge University PressPrint publication year: 2012